Malaria Clinical Trial
— SAPOTOfficial title:
Intermittent Preventive Treatment in Pregnancy With Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine to Prevent Malaria Infection and Reduce Adverse Pregnancy Outcomes in Papua New Guinea - a Randomised Controlled Trial
This trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) plus dihydroartemisinin-piperaquine (DP) significantly reduces the risk of malaria infection (primary outcome) and adverse birth outcomes (key secondary outcome) in an endemic area of Papua New Guinea (PNG), compared to IPTp with SP alone (the current standard of care). To test this hypothesis a double-blinded, placebo-controlled, phase-III, superiority trial will individually randomize 1,172 HIV-uninfected pregnant women enrolled from 12-26 gestational weeks in equal proportions to one of two IPTp arms: 1) SP given every for weeks, or 2) SP+DP given every 4 weeks. DP placebos will be used to ensure adequate blinding is achieved in the study and follow-up will end 28 days after giving birth.
Status | Recruiting |
Enrollment | 1172 |
Est. completion date | December 2025 |
Est. primary completion date | February 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - Pregnant women between 12-26 weeks' gestation - 16 years of age or older - Viable singleton intrauterine pregnancy - Permanent resident of the study area - Willing to adhere to scheduled and unscheduled study visit procedures - Willing to birth in a study clinic or hospital - Able to provide written informed consent Exclusion Criteria: - Multiple pregnancy (i.e. twins/triplets) - Known heart ailment or other chronic medical condition requiring frequent hospital care - Active medical problem requiring inpatient evaluation at the time of screening - Severe malformations or non-viable pregnancy if observed by ultrasound - Antimalarial therapy in the prior two weeks - Unable to provide written informed consent - Known allergy or contraindication to any of the study drugs - Early or active labour - Known HIV-positive status |
Country | Name | City | State |
---|---|---|---|
Papua New Guinea | Papua New Guinea Institute of Medical Research | Madang | Madang Province |
Lead Sponsor | Collaborator |
---|---|
Menzies School of Health Research | Curtin University, Liverpool School of Tropical Medicine, Papua New Guinea Institute of Medical Research, University of Melbourne |
Papua New Guinea,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Malaria infection in pregnancy | 'Malaria infection in pregnancy' is a composite outcome, defined as one or more episode of P. falciparum and/or P. vivax infection, detected by microscopy and/or qPCR in peripheral blood or placental blood, or P. falciparum and/or P. vivax infection, detected as active infection on placental histology. The surveillance period will run from two weeks after the first dose of the first monthly treatment up until and including delivery (numerator) in women who attend at least one scheduled or unscheduled visit during the surveillance period (denominator).
Proportion of women with 'malaria infection in pregnancy' |
Starting two weeks after initial dose until and including delivery | |
Secondary | Adverse pregnancy outcome | Composite adverse birth outcome is defined as the occurrence of any of the following:
Spontaneous miscarriage: Fetal loss <28 weeks of gestational age Stillbirth: Infant born deceased at =28 weeks of gestational age Low birth weight (LBW): Live birth with birth weight <2,500 grams Preterm birth (PTB): Live birth <37 weeks gestational age Small-for-gestational age (SGA): Live birth with birth weight-for-gestational-age <10th percentile of the INTERGROWTH-21st reference Neonatal death: Live birth with neonatal death within the first 28 days of life Prevalence of adverse pregnancy outcome |
Time of delivery up to 28 days postpartum | |
Secondary | Clinical malaria during pregnancy | Incidence of new episodes of fever or history of fever plus positive RDT confirmed by microscopy and/or qPCR during pregnancy | Starting two weeks after initial dose until and including delivery | |
Secondary | Parasitemia during pregnancy | Proportion of samples with parasites detected in maternal peripheral blood samples by microscopy or qPCR | Starting two weeks after initial dose until and including delivery | |
Secondary | Composite placental malaria detected by microscopy, qPCR or by histology | Prevalence of placental parasites by microscopy, qPCR, or placental histology | At time of delivery | |
Secondary | Placental malaria detected by microscopy | Prevalence of parasites in placental blood by microscopy | At time of delivery | |
Secondary | Placental malaria detected by qPCR | Prevalence of parasites in placental blood by qPCR | At time of delivery | |
Secondary | Active placental malaria detected by histology | Prevalence of active infection (presence of parasites) on histology | At time of delivery | |
Secondary | Past placental malaria detected by histology | Prevalence of past infection (pigment only) on histology | At time of delivery | |
Secondary | Placental malaria detected by histology | Prevalence of placental infection (active or past) on histology | At time of delivery | |
Secondary | Composite fetal loss and neonatal death | Prevalence of fetal loss (spontaneous miscarriage or stillbirth) and neonatal death | Time of delivery up to 28 days postpartum | |
Secondary | Composite of SGA-LBW-PTB | Prevalence of small for gestational age, low birth weight, and preterm birth | At time of delivery | |
Secondary | SGA | Prevalence of small for gestational age using the new Intergrowth-21st population reference's 10th centile | At time of delivery | |
Secondary | LBW | Prevalence of low birth weight | At time of delivery | |
Secondary | PTB | Prevalence of preterm birth | At time of delivery | |
Secondary | Birth weight | Mean birthweight | At time of delivery | |
Secondary | Neonatal length | Neonatal length | At time of delivery | |
Secondary | Maternal nutritional status | Changes in maternal body mass index (BMI) | 8 months from randomisation | |
Secondary | Maternal nutritional status | Changes in maternal mid-upper arm circumference (MUAC) | 6 months from randomisation | |
Secondary | Maternal anemia during pregnancy and at delivery | Proportion of routine haemoglobin measurements <100 g/L | 6 months from randomisation | |
Secondary | Maternal hemoglobin levels during pregnancy and at delivery | Mean hemoglobin (g/L) at the third trimester antenatal visit and at delivery | 6 months from randomisation | |
Secondary | Congenital anemia | Prevalence of anaemia (Hb <130 g/L) from newborn cord blood | At delivery | |
Secondary | Maternal gametocyte carriage during pregnancy and at delivery | Proportion of P. falciparum positive samples with gametocytes at the third trimester antenatal visit and at delivery, by light microscopy and RT-qPCR | 6 months from randomisation | |
Secondary | Molecular markers of DP resistance | Proportion of parasite positive samples with molecular markers of DP resistance | 6 months from randomisation | |
Secondary | Molecular markers of SP drug resistance | Proportion of parasite positive samples with molecular markers of SP resistance | 6 months from randomisation | |
Secondary | Maternal mortality | he death of a woman while pregnant or within 42 days of the end of pregnancy, irrespective of the duration and site of the pregnancy, but not from accidental or incidental causes | 8 months from randomisation | |
Secondary | Congenital malformations | Any visible external congenital abnormality on surface examination | 8 months from randomisation | |
Secondary | Other SAEs and AEs | Incidence of AEs and SAEs | 8 months from randomisation | |
Secondary | (History) of vomiting study drug | Prevalence of vomiting investigational product (IP) twice at the same IP administration visit | 6 months from randomisation | |
Secondary | Dizziness | Prevalence of dizziness after a course of IP | 6 months from randomisation | |
Secondary | Gastrointestinal complaints | Prevalence of gastrointestinal complaints after a course of IP | 6 months from randomisation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02536222 -
Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts
|
Phase 4 |